



ADULT MEDICATION GUIDELINE

Labetalol Injection

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and
Breastfeeding](#)

Restrictions

[Formulary: Restricted](#)

[HIGH RISK Medication](#) 

Medication Class

Beta blocker

Presentation

Ampoule: 50mg/10mL

Storage

Store at room temperature, below 25°C

Ampoule: Protect from light.

Infusion solution: Discard after 6 hours if kept below 25 °C **or** after 24 hours if kept between 2 to 8 °C. Do not freeze.

Dose

Acute treatment of severe hypertension in pregnancy

IV injection: 20mg labetalol (4mL) undiluted over 2 minutes. Dose can be repeated every 10 minutes (titrated to blood pressure) to a maximum of 4 doses of 20mg (80mg = 16mL).

If 2 bolus doses are insufficient to control blood pressure, consider IV therapy via infusion.

The maximal effect usually occurs within 5 minutes of each dose.

IV infusion: See below

Maximum total 24 hours dose is 300mg (injection plus infusion)

Administration

IV injection

Inject undiluted solution slowly over 2 mins.

IV infusion

Step 1 Dilution:

Withdraw 40mL sodium chloride 0.9% from a 100mL bag of sodium chloride 0.9%. Draw up 200mg labetalol (40 mL) and add to remaining 60 mL in the bag of sodium chloride 0.9%. Final concentration is 2 mg/mL.

Step 2 Administration:

Start infusion pump at 10 mL/hour (20 mg/hour). Titrate to stabilise blood pressure by adjusting (doubling, maintaining or halving) the infusion as required every 15 to 30 minutes to a maximum dose of 80 mL/hour (160 mg/hour).

Discontinue by weaning over 1-2 hours when clinically appropriate.

Monitoring

Blood pressure and heart rate should be monitored during and every 15-30 mins following IV administration until stabilised, then record hourly as clinically appropriate.

Patients should always be kept in a supine position during and for up to 3 hours post IV administration due to potential orthostatic hypotension

Pregnancy

1st Trimester: Considered safe to use

2nd Trimester: Monitoring required

3rd Trimester: Monitoring required

Breastfeeding

Considered safe to use

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

[Hypertension in pregnancy: Medical management](#)

[Hypertension in pregnancy – midwifery care](#)

WNHS Pharmaceutical and Medicines Management Guidelines:

[Medication Administration](#)

References

Society of Hospital Pharmacists of Australia. Labetalol. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2022 [cited 2023 Feb 14]. Available from: <http://aidh.hcn.com.au>

The Royal Women's Hospital. Labetalol. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2022 [cited 2023 Feb 14]. Available from: <https://thewomenspbmg.org.au/>









Lowe SA, Bowyer L, Lust K, McMahon LP, Morton MR, North RA, et al. Guideline for the management of hypertensive disorders of pregnancy. Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) Endorsed Guidelines [Internet]. 2014 [cited 2023 Mar 10]. Available from: [Guideline for the Management of Hypertensive Disorders of Pregnancy](#)

South Australian Maternal, Neonatal & Gynaecology Community of Practice. Hypertensive Disorders in Pregnancy. South Australian Perinatal Practice Guidelines. [Internet]. 2020 [cited 2023 Feb 14]. Available from: [Hypertensive Disorders in Pregnancy \(sahealth.sa.gov.au\)](https://sahealth.sa.gov.au/)

Ballarat Health Services. Labetalol (Intravenous - severe hypertension in pregnancy). Ballarat Health Services Drug Guideline DRG0035 [Internet]. 2020 [cited 2023 Mar 15]. Available from: [gddrg0035-25948-63478.pdf \(bhs.org.au\)](https://bhs.org.au/gddrg0035-25948-63478.pdf)

3centres Collaboration Consensus Guideline – Hypertension in Pregnancy, Preeclampsia and Eclampsia. [Internet] 2012 [cited 2020 Jun 10]. Available from: www.pers.org.au/Assets/45/1/3CENTRESPREECLAMPSIA.pdf

McEvoy GK et al. Handbook on Injectable Drugs (Trissel): Labetalol hydrochloride. American Society of Health System Pharmacists. [Internet]. 2018. [cited 2020 Jun 10].

Keywords	Labetalol injection, Labetalol SXP, hypertension				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	5.0				
Date First Issued:	May 2015	Last Reviewed:	14/02/2023	Review Date:	14/02/2026
Endorsed by:	Medicines and Therapeutics Committee			Date:	April 2023
NSQHS Standards Applicable:	<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety </div> <div style="width: 48%;"> <input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration </div> </div>				
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2023

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.